Effect of chronic and intermittent calorie restriction on serum adiponectin and leptin and mammary tumorigenesis.
The effect of chronic (CCR) and intermittent (ICR) caloric restriction on serum adiponectin and leptin levels was investigated in relation to mammary tumorigenesis. 10-wks old MMTV-TGF-α female mice were assigned to ad libitum fed (AL; AIN-93M diet), ICR (3-week 50% caloric restriction, AIN-93M-mod diet, 2× protein, fat, vitamins, and minerals followed by 3-wks 100% AL consumption of AIN-93M), and CCR (calorie and nutrient intake matched for each 6-wks ICR cycle, ∼ 75% of AL) groups. Mice were sacrificed at 79 (end of restriction) or 82 (end of refeeding) wks of age. Serum was obtained in cycles 1, 3, 5, 8, 11, and terminal. Mammary tumor incidence was 71.0%, 35.4%, and 9.1% for AL, CCR, and ICR mice, respectively. Serum adiponectin levels were similar among groups with no impact of either CCR or ICR. Serum leptin level rose in AL mice with increasing age but was significantly reduced by long-term CCR and ICR. The ICR protocol was also associated with an elevated adiponectin/leptin ratio. In addition, ICR-restricted mice had increased mammary tissue AdipoR1 expression and decreased leptin and ObRb expression compared with AL mice. Mammary fat pads from tumor-free ICR-mice had higher adiponectin expression than AL and CCR mice whereas all tumor-bearing mice had weak adiponectin signal in mammary fat pad. Although we did not show an association of either adiponectin or leptin with individual mice in relation to mammary tumorigenesis, we did find that reduced serum leptin and elevated adiponectin/leptin ratio were associated with the protective effect of intermittent calorie restriction.
1The Hormel Institute, University of Minnesota, Austin and 2Mayo Clinic, Rochester, Minnesota 55912, USA.
Olga P
OP
Rogozina
Melissa J L
MJ
Bonorden
Christine N
CN
Seppanen
Joseph P
JP
Grande
Margot P
MP
Cleary
D052242:Adiponectin / Q000097:blood*; D000818:Animals; D015153:Blotting, Western; D031204:Caloric Restriction; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008325:Mammary Neoplasms, Experimental / Q000097:blood* / Q000517:prevention & control; D051379:Mice; D008822:Mice, Transgenic; D016211:Transforming Growth Factor alpha / Q000235:genetics / Q000378:metabolism
D052242:Adiponectin; D020738:Leptin; D016211:Transforming Growth Factor alpha
Biochim Biophys Acta. 2002 Oct 21;1592(2):107-16
12379472
Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43
9316608
Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
16859394
Hypertens Res. 2007 Dec;30(12):1199-203
18344625
J Appl Physiol (1985). 2009 Mar;106(3):911-8
19095749
Neoplasma. 2003;50(1):41-6
12687277
Cancer Lett. 2006 Jun 8;237(1):137-42
16011872
Clin Cancer Res. 2003 Nov 15;9(15):5699-704
14654554
Clin Cancer Res. 2004 Jul 1;10(13):4325-31
15240518
Cell. 1995 Dec 29;83(7):1263-71
8548812
Mol Cell Endocrinol. 2002 Feb 25;188(1-2):219-26
11911959
Obes Rev. 2004 Aug;5(3):153-65
15245384
J Postgrad Med. 2009 Jan-Mar;55(1):45-54
19242081
Biochem Biophys Res Commun. 2002 Apr 26;293(1):622-8
12054648
Int J Cancer. 1999 Feb 9;80(4):523-6
9935151
Oncol Lett. 2010 Jan;1(1):167-176
22966277
Metabolism. 2009 Aug;58(8):1096-101
19477470
Obes Rev. 2003 Aug;4(3):157-73
12916817
Physiol Res. 2006;55(3):277-83
16083306
J Mol Med (Berl). 2010 Jul;88(7):677-86
20339829
Int J Obes Relat Metab Disord. 2004 Aug;28(8):956-62
15254485
Exp Biol Med (Maywood). 2007 Jan;232(1):70-80
17202587
JAMA. 2004 Mar 10;291(10):1226-30
15010444
J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
17192291
J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
17213279
Nature. 2003 Jun 12;423(6941):762-9
12802337
Nutr Cancer. 2002;44(2):162-8
12734063
Nutr Cancer. 2004;50(2):174-80
15623464
J Nutr. 1989 Feb;119(2):286-91
2493082
Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):836-43
12223427
Endocr Relat Cancer. 2007 Jun;14(2):189-206
17639037
Endocr Relat Cancer. 2009 Dec;16(4):1197-210
19661131
Arch Physiol Biochem. 2008 Feb;114(1):71-83
18465361
Int J Oncol. 2004 Jun;24(6):1529-35
15138597
Metabolism. 2011 Apr;60(4):569-78
20619426
Breast Cancer Res. 2007;9(6):R91
18162139
Oncol Res. 2009;18(5-6):269-77
20225764
J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31
14557461
J Lipid Res. 2007 Oct;48(10):2212-9
17607017
Int J Oncol. 2007 Jun;30(6):1499-509
17487372
Int J Obes Relat Metab Disord. 2003 Sep;27(9):1066-71
12917712
Br J Cancer. 1992 Jun;65(6):845-51
1616856
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2088-94
16609020
Cytokine Growth Factor Rev. 2009 Jun;20(3):193-201
19520599
Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E861-5
12217905
J Clin Endocrinol Metab. 2005 Nov;90(11):6185-91
16091498
J Nutr Biochem. 2008 Jun;19(6):371-5
17614271
J Cell Physiol. 2006 Apr;207(1):12-22
16110483
Cancer Prev Res (Phila). 2009 Apr;2(4):338-44
19336733
Cell Res. 2008 Nov;18(11):1154-6
18957939
Med Oncol. 2007;24(4):361-6
17917082
J Clin Oncol. 2006 May 10;24(14):2137-50
16682732
Int J Cancer. 2003 Sep 20;106(5):766-70
12866038
Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S94-100
12570341
Horm Res. 2007;67(6):296-300
17284923
Cancer Causes Control. 2001 Jan;12(1):13-21
11227921
Int J Oncol. 2006 Apr;28(4):985-93
16525650
Eur J Clin Nutr. 2002 Jul;56(7):593-600
12080397
Eur Rev Med Pharmacol Sci. 2008 Jan-Feb;12(1):33-9
18401970
Free Radic Biol Med. 2007 Mar 1;42(5):665-74
17291990
CA Cancer J Clin. 2007 Nov-Dec;57(6):326-40
17989128
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6494-8
7604020
Endocrinology. 2005 Nov;146(11):4934-42
16037380
Endocrine. 2005 Feb;26(1):19-24
15805581
Int J Mol Med. 2000 Apr;5(4):421-6
10719061
Breast Cancer Res Treat. 2004 Aug;86(3):191-6
15567935
Endocr Relat Cancer. 2007 Sep;14(3):669-77
17914097
Am J Pathol. 1992 May;140(5):1131-46
1316084
J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11
12441326
Endocrine. 2006 Feb;29(1):81-90
16622295
Cancer Lett. 2007 Jun 8;250(2):229-36
17123704
Br J Cancer. 2008 Jan 29;98(2):370-9
18182989
Cancer Res. 1989 Aug 1;49(15):4130-4
2501021
Proc Soc Exp Biol Med. 1991 Apr;196(4):381-4
1901169
Cancer Prev Res (Phila). 2009 Aug;2(8):712-9
19654106
Cancer Res. 2006 Dec 1;66(23):11462-70
17145894
Exp Gerontol. 2008 Jul;43(7):706-13
18434057
Carcinogenesis. 2002 May;23(5):817-22
12016155
Mol Cell Endocrinol. 2007 Oct 15;277(1-2):26-34
17716811
Neuropeptides. 2009 Aug;43(4):321-5
19539991
Ann Intern Med. 2010 Jan 19;152(2):93-100
20083828
Jpn J Clin Oncol. 2001 Sep;31(9):424-7
11689595
Cancer Res. 1988 Aug 1;48(15):4276-83
3390824
Clin Endocrinol (Oxf). 2004 Sep;61(3):332-8
15355449
Nutr Cancer. 2009;61(2):265-75
19235043
J Clin Endocrinol Metab. 2001 Aug;86(8):3815-9
11502817
Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9
10845877
Oncol Rep. 2008 Apr;19(4):905-11
18357374
Int J Cancer. 1987 Jun 15;39(6):737-44
3583452
JAMA. 1997 Nov 5;278(17):1407-11
9355998
Cancer Lett. 2006 Jun 8;237(1):109-14
16019138
Int J Oncol. 2002 Dec;21(6):1285-92
12429979
Int J Cancer. 2006 Mar 15;118(6):1414-9
16206269
Cell. 1990 Jun 15;61(6):1147-55
2161707
Chin Med J (Engl). 2007 Sep 20;120(18):1592-6
17908478
Med Hypotheses. 2007;69(6):1290-2
17509773
J Nutr Biochem. 2010 Mar;21(3):188-95
19195863
Prostate. 2009 Feb 15;69(3):317-26
19016490
Breast Cancer Res Treat. 2009 Mar;114(1):71-83
18392696
Cancer Prev Res (Phila). 2009 Aug;2(8):720-31
19656771
Clin Cancer Res. 2004 Oct 1;10(19):6466-75
15475434
J Nutr. 1946 Mar;31:363-75
21021020
J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7
15001594
Am J Clin Nutr. 2006 Nov;84(5):1033-42
17093155
Int J Cancer. 2004 Sep 20;111(5):762-71
15252848
Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9
16678125
J Nutr Biochem. 2010 May;21(5):413-7
19423320
Eur J Endocrinol. 1996 Dec;135(6):649-50
9025704
Eur J Intern Med. 2003 Nov;14(7):415-418
14614973
Cancer Causes Control. 2000 May;11(5):383-8
10877331
J Med. 2002;33(1-4):73-86
12939106